??????????? ??????????? ??????????????????????????????????????????????????????????????????Negotiations around the 2022 reauthorization counsel that sector priorities incorporate greater software of authentic-environment evidence, regulatory certainty, and increased interaction among FDA and market in the drug application system.Immediately after co